Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 1 3

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

pembrolizumab 28Cisplatin 24Oxaliplatin 22Irinotecan 22Fluorouracil 22Capecitabine 20Leucovorin 17Paclitaxel 16Cyclophosphamide 14Trastuzumab 12Nivolumab 11Carboplatin 11Gemcitabine 10Bevacizumab 10Docetaxel 9fludarabine 8aldesleukin 8S 1 (combination) 8Ramucirumab 7130-nm albumin-bound paclitaxel 7atezolizumab 6Albumin-Bound Paclitaxel 6Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Biopsy 5veliparib 4tislelizumab 4spartalizumab 4dehydroftorafur 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Stomach Neoplasms × durvalumab × Clear all
NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

I-Mab Biopharma US Limited

Phase 1 Recruiting
330 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT02572687 2021-01-20

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Eli Lilly and Company

Phase 1 Completed
85 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Neoplasm Metastasis, Stomach Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡